months without effect. Since diagnosis, prednisone was never less than at 10 mg/day with frequent dose escalation depending on disease activity. Pre-transplant, she had diffuse active skin lesions covering 20% of her body surface area (Figure 1) .
HSCT was well tolerated. The duration of ANC less than 500/mcl was 7 days. Culture-negative neutropenic fever was present for 1 day. Other transplant toxicities were grade I (by NCI toxicity criteria) nausea and grade II anorexia. Otherwise, the transplantation course was without unexpected toxicity. No early or late opportunistic infections have occurred.
Following HSCT, skin lesions gradually disappeared over 2 months and prednisone was tapered off within 4 months. Serum autoantibody titer gradually decreased from 1:640 pre-transplant to 1:160 at 6 months and 1:20 at 12 months post-transplant, respectively. A complete cutaneous remission was maintained until 10 months following HSCT, when a few small foci of erythematous plaques occurred on the nose and scalp. Punch biopsy of a lesion revealed the recurrence of PF that responded to intermittent topical corticosteroids alone. No other lesions have occurred and no systemic therapy has been required for 19 months following HSCT. Cutaneous autoimmune bullous disorders represent an array of distinct skin diseases including PV, PF, paraneoplastic pemphigus, bullous pemphigoid, CP, pemphigoid gestationis, dermatitis herpetiformis, linear IgA disease and epidermolysis bullosa acquisita, among others. Many of these disorders have known autoreactive antibodies. The hallmark of PF is IgG autoantibodies directed against desmoglein 1, a 160 kDa transmembrane glycoprotein that is expressed on the cell surface of keratinocytes. 4 As the autoantibodies in PF and PV are pathogenic and play a primary role in blister formation, a direct correlation exists between disease activity and antibody titer. 5 Patients with PF present clinically with superficial, fragile vesicles that rupture to form well-demarcated, scaly, crusted erosions on an erythematous base.
In patients with widespread disease, systemic corticosteroids are first-line therapy and result in rapid remissions in the majority of patients. 6 However, the significant morbidity associated with prolonged systemic corticosteroids limits their utility. Commonly utilized steroid-sparing agents include azathioprine, CY, gold salts, cyclosporine, MTX, MMF, dapsone, tetracycline and minocycline. Although most cases can be controlled with conventional therapies, severe cases may be refractory and a breakthrough therapy is needed.
While there are no prior reports of HSCT for bullous skin diseases, Nousari et al have reported cases of pemphigus treated with high-dose CY without stem cell transplant. [7] [8] [9] To our knowledge, this is the first report of autologous HSCT transplantation for autoimmune bullous skin diseases. Whether our regimen using high-dose CY and rATG with CD34 selected PBSC is superior to the regimen using high-dose CY without stem cells is currently unknown. Our patient responded dramatically with a drugfree remission. While a very limited relapse (o1% body surface area involved) occurred at 10 months post HSCT, it was transient. Re-induction of clinical remission readily occurred to only topical corticosteroid therapy. Although longer observation and more patients are necessary, our result suggests that further studies of HSCT in refractory autoimmune bullous skin disorders appear warranted. 
